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ABSTRACT
Objective: Present research work aims toward codelivery of two hydrophobic drugs, curcumin (CRM) and duloxetine hydrochloride (DXH) through 
self-nanoemulsifying drug delivery systems (SNEDDS).
Methods: Initially, binary mixture in the ratio of 1:1 was prepared and then loaded into SNEDDS. Box-Behnken design (BBD) was adopted to develop 
SNEDDS. As per the optimal design, 13 SNEDDS prototypes were prepared. Castor oil, tween-80 and Transcutol P® were used as oil, surfactant, and 
cosurfactant, respectively. To 1 mL of SNEDDS, 30 mg each of CRM and DXH was loaded (CRM-DXH- SNEDDS).
Results: The design revealed that for mean droplet size, polydispersity index (PDI), as well as percentage drug loading, all the three factors, i.e. ratio of 
oil (a), surfactant (b), and cosurfactant (c) were found to give significant effect. Factor B showed the most significant effect on mean droplet size (y1). 
In case of PDI (y2), factors B and C exerted maximum influence, whereas, Factor A has shown non-significant effect. For percentage drug loading of 
drugs (y3 and y4), all the three factors were found to have the most significant effect. The optimized batch of CRM-DXH- SNEDDS having composition 
castor oil, tween-80, and Transcutol P® in the ratio: 2.17:5.22:2.61, revealed that the mean drug loading (%) of CRM and DXH in an optimized batch of 
SNEDDS was found to be 87.22±1.87 and 92.32±0.19%, respectively. The mean droplet size, PDI, and zeta potential of formed SNEDDS were observed 
as 113.14±1.14 nm, 0.20±0.026, and −13.2 mV, respectively.
Conclusion: BBD provided optimal formula composition for SNEDDS for obtaining desirable drug loading, emulsion droplet size, and zeta potential.
Keywords: Curcumin, Duloxetine hydrochloride, Binary mixture, Curcumin - duloxetine hydrochloride - self-nanoemulsifying drug delivery systems, 
Box Behnken design, Castor oil, Transcutol P®, Tween-80.
INTRODUCTION
Duloxetine hydrochloride (DXH), an antidepressant possesses a 
significant pain-relieving effect. It is the first prescription drug that 
was approved by the Food and Drug Administration for treatment 
of painful diabetic neuropathy [1,2]. It is reported to exert its action 
through inhibition of both serotonin (5-HT) and norepinephrine (NE) 
reuptake [3-5]. These serotonin/noradrenaline reuptake inhibitors are 
also used clinically as a treatment modality for neuropathic pain [4].
Curcumin (CRM) (Curcuma longa) is well-established biologically active 
natural material derived from turmeric plants [6]. CRM inhibits mitogen-
activated protein kinases [7] and has been reported for an antioxidant, 
anti-inflammatory, immunomodulatory, cancer chemopreventive, 
antiulcer, and neuroprotective activities [8-14].
Therapeutic modalities provide only partial relief, and there is no single 
treatment that works for all conditions of neuropathy. Hence, there is 
an ample scope to develop new medicine, particularly, a combination 
of one of synthetic and second of plant origin. Therefore, an attempt 
has been done to coadminister DXH and CRM for effective treatment of 
neuropathic pain using a suitable delivery system.
The major impediments that restrict the choice of delivery system for 
concomitant delivery of those two drugs include the poor aqueous 
solubility of both the drugs and degradation of DXH in the harsh 
environment of the stomach [15,16]. This ultimately leads to poor 
oral bioavailability of drugs when administered orally. A number of 
initiatives have been taken in the past to develop oral formulations 
of DXH and CRM [5,17-19]; however, they were not found to be very 
successful clinically.
Self-nanoemulsifying drug delivery systems (SNEDDSs) have been 
reported to overcome such challenges. They have been successfully 
reported delivering poorly soluble drugs as well as drugs that get 
degraded through oral route [20,21]. Mechanisms that are involved in 
the absorption of oils/lipids include passive diffusion, or pinocytosis, or 
absorption through lymphatic system [22].
Combination of CRM and DXH, loaded as SNEDDS, is expected to 
increase drug solubilization, increase in surface area of droplets due 
to nanometer size range, surface induced permeability that could allow 
very large distribution of the drug in the GIT, and protection against 
enzymatic/acidic degradation [23,24]. Based on this hypothesis, 
an attempt has been made to formulate SNEDDS for CRM-DXH 
binary mixture. The formulation was developed using the design of 
experiments (DoE). Box-Behnken design (BBD) was used to investigate 
the formulation variables that could affect droplet size, zeta potential, 
and percentage drug loading of CRM and DXH. BBD is a systematic 
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approach that helps researchers to understand the process variables 
that could significantly affect the product quality. In this way, the non-
significant variables could be eliminated.
MATERIALS AND METHODS
Materials used
DXH was gifted by Sun Pharma, Mumbai, India. CRM was procured from 
Central Drug House (CDH) (P) Ltd from Mumbai (India). Polyethylene 
glycol (PEG) 200 and 600, propylene glycol, olive oil, castor oil, 
eucalyptus oil, oleic acid, polyvinyl alcohol, tween 60 and 80, span 20 
and 80, and ethanol were procured from CDH, India. Transcutol P® was 
received as gift sample from M/s Gattefosse, India. All other chemicals 




The solubility of CRM and DXH in various oils, surfactants, and 
cosurfactants were determined using shake flask method [25-27]. The 
solubility studies have been performed in oils (olive oil, eucalyptus 
oil, cottonseed oil, sunflower oil, castor oil, peanut oil, and oleic acid), 
surfactants (tween 60 and 80, span 20 and 80, and PEG 200 and 600), 
and cosurfactant (Transcutol P® and ethanol) to find suitable oil, 
surfactant, and cosurfactant for the formulation of SNEDDS. To 1mL of 
each oil, surfactant, and cosurfactants, 30 mg each of DXH and CRM was 
added, and the mixtures were vortexes for 2 min at regular interval up 
to 48 h. The solutions were centrifuged at 3500 rpm for 15 min, and the 
supernatants were collected. Oily solutions were diluted with n-hexane 
whereas surfactant and cosurfactant solutions were diluted with distilled 
water for analysis. Samples were analyzed using high-performance 
liquid chromatography (HPLC) method that has been already developed 
and validated for the estimation of CRM and DXH [28].
Screening of surfactants for emulsifying ability and construction 
of ternary phase diagrams
Emulsification ability of various surfactants was screened [25]. Ternary 
mixtures were prepared by mixing oil, surfactant, and cosurfactant. 
Various combinations of surfactant, cosurfactant, and oil were used, 
and their concentrations were varied in each formulation. Phase 
diagrams were constructed to identify good self-emulsifying region. All 
studies were carried out in triplicate, with similar observations being 
made between repeats. The self-emulsifying performance was visually 
assessed after dilution using purified water. To find out the SNEDDS 
region, 324 prototypes of SNEDDS were formulated by varying the 
composition of oil, surfactants, and cosurfactants. The ratio of oil and 
Smix (mixture of surfactant and cosurfactant) was kept as 1:9, 2:8, 3:7, 
4:6, 5:5, 6:4, 7:3, 8:2, and 9:1, respectively. In the present study, Smix 
was kept in the ratio of 1:1, 1:2, and 2:1, respectively. Three different 
oils (castor oil, olive oil, and sunflower oil), two different surfactants 
(tween-80 and PEG-200), and two different cosurfactants (Transcutol 
P® and ethanol) have been used.
Hence, for each oil 27 batches each were prepared using Transcutol 
P® and ethanol as cosurfactant, respectively, while keeping Tween-80 
as a surfactant. Similarly, 27 batches were prepared for each oil using 
Transcutol P® and ethanol as cosurfactant, respectively, keeping PEG-
200 as a surfactant. Summarizing the above statement for each oil, 
108 batches of SNEDDS prototypes were prepared. The mixture was 
vortexed for 15 min using vortex mixer (CM 101 CYCLO MIXER, REMI, 
India). Further, the prepared isotropic mixtures were diluted to 500 mL 
of double distilled water and stirred at 500 rpm at a temperature of 
37±5°C. The ease of formation of the emulsion was also noted. The 
resulting emulsions were allowed to stand for 2 h and then observed 
visually for relative turbidity.
DOE for selection of optimized batch for CRM-DXH- SNEDDS
From the ternary phase diagram, nanoemulsion region was selected. 
The results revealed that formulations wherein castor oil were 
used as lipid phase and Smix (ratio of tween 80 and Transcutol P®) in 
ratios of 1:1 (F301-303), 2:1 (F311-313), and 1:2 (F321-323) have shown the 
largest nanoemulsion area. Hence, these three excipients have been 
selected for further formulation development. A set of experiments 
with BBD was adopted to develop the SNEDDS of CRM-DXH binary 
mixture. The amount of CRM and DXH was kept constant, type of oil, 
and type of surfactant and cosurfactant were kept constant for all 
the experiments and ratio of castor oil, tween-80, and Transcutol P® 
was varied.
All these factors were operated at three levels (+1, 0, and -1). Design-
Expert® Dx 9.0.1 software was used to conduct the study. A total of 13 
experiments were designed by the software. Experiments were run 
in random order to increase the predictability of the model. Table 1 
shows the independent factors and their design level used in this study. 
Table 2 lists out the formula composition of SNEDDS with respect to 
ratios as mentioned in DOE. All the formulated batches were subjected 
for analysis of emulsion droplet size analysis, percentage drug loading, 
and polydispersity index (PDI).
Characterization of prepared SNEDDS
Calculation of drug loading
As per the design mentioned in DOE, SNEDDS was prepared by adding 
CRM and DXH (in the ratio of 1:1) equivalent to 30 mg to each batch 
in 1 mL mixture of castor oil, tween-80, and Transcutol P® (Table 3). 
These was place in a vortex mixer for vortexing (CM 101 CYCLO MIXER, 
REMI, India) for 15 min and then added to 500 mL of double distilled 
water kept in a 1000 mL glass beaker. The diluted mixture was stirred 
at 500 rpm at a temperature of 37°C. Sample (5 mL) was withdrawn 
and filtered through 0.2 µm membrane filter (Millipore, Germany) and 
centrifuged at 10000 rpm for 15 min. The collected supernatant was 
analyzed using HPLC [28]. The percentage drug loading was calculated 
as per equation 1.
Area of test drug present in SNEDDS%Drug loading= 100
Absorbance of known standard
×
 (1)
Particles size and zeta potential
Photon correlation spectroscopy using Malvern zeta sizer nano ZS90 
(Malvern Instruments Ltd., UK) with a 50 mV laser at a fixed angle of 
90° was used to measure measurement of droplet size, PDI, and zeta 
potential. Measurements were carried out at 25°C using disposable 
Table 1: Variables for Box‑Behnken study for CRM‑DXH‑ SNEDDS
Independent factors Design level
Uncoded Coded Uncoded Coded
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Table 2: Formula composition for CRM-DXH-SNEDDS
Ingredients Quantity/batch (g)
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polystyrene cells and disposable plain folded capillary cells after dilution. 
L-SNEDDS/S-SNEDDS sample (100 μL) was diluted with 100 mL double 
distilled water. Each run underwent 12 sub-runs for a period of 2 min. 
Each study was repeated in triplicate to record the mean data [27,29].
Statistical analysis
Statistical analysis of obtained data was carried out either by analysis 
of variance (ANOVA) or Tukey’s multiple comparison tests. The 
dissolution profile was compared using model-independent analysis 
(F2 comparison) as discussed in Shah et al. 1998 [30].
RESULTS AND DISCUSSIONS
Solubility studies of CRM and DXH in oils, surfactants, and 
cosurfactants
The observed results of solubility study indicated in Table 4 that the 
solubility of CRM in oil was in the following order:
Sunflower oil ˃ eucalyptus oil ˃ peanut oil ˃ olive oil ˃ castor oil ˃ 
cottonseed oil ˃ oleic acid
Among surfactants the solubility of CRM was found to be:
Tween-80 ˃ PEG200 ˃ PEG600 > Tween-60 > Span-20 > Span-80
Among cosurfactant it was found to be:
Ethanol ˃ Transcutol P®
Similarly, solubility of DXH in various oils was tested, and order of 
solubility was:
Eucalyptus oil ˃ sunflower oil ˃ castor oil ˃ cottonseed oil ˃ olive oil ˃ 
peanut oil ˃
oleic acid
Solubility of DXH in surfactant was as follows:
PEG-600 ˃ PEG-200 ˃ Tween-80 > Tween-60 > Span-20 > Span-80
Solubility of DXH in cosurfactant was in the following order:
Ethanol ˃ Transcutol P®
Since, an optimum solubility of both the drugs was found in sunflower 
oil, olive oil, and castor oil; these were selected as oils for preparation 
of ternary phase diagram. Among, surfactants and solubility were 
found to be good in tween-80 and PEG-200 and among cosurfactants, 
in Transcutol P®, and ethanol.
Screening of oils, surfactants, and cosurfactants for emulsification 
ability and construction of ternary phase diagram
A series of SEDDS were prepared and were visually observed for their 
self-emulsifying properties. The formed emulsions were analyzed as 
SNEDDS, SMEDDS, and normal emulsion. In the presence of CRM-DXH, 
pseudoternary phase diagram was constructed for the identification 
of self-emulsifying region and to optimize the concentration of oil, 
surfactant, and cosurfactant in the formulation of SEDDS. Ternary phase 
diagram for formulations F1-F29 was prepared, wherein various ratios of 
olive oil, PEG-200, and Transcutol P® were used. For formulations F31-F59, 
the ternary phase diagram includes various ratios of olive oil, PEG-200, 
and ethanol. Formulations F61 to F89, wherein various ratios of olive oil, 
tween-80, and Transcutol P® and for formulations F91-119, various 
ratios of olive oil, tween-80, and ethanol were used for the preparation 
of ternary phase diagram. The ternary phase diagram for formulations 
F121–F149, various ratios of sunflower oil, PEG-200, and Transcutol P® 
were used, and for formulations F151–F179, various ratios of sunflower 
oil, PEG-200, and ethanol were used. The ternary phase diagram for 
formulations F181-F209, various ratios of sunflower oil, tween-80, and 
Transcutol P® were used, and for formulations, F211 to F239, various ratios 
of sunflower oil, tween-80, and ethanol were used. The ternary phase 
diagram for formulations F241-F269, various ratios of castor oil, PEG-200, 
and Transcutol P® were used, and for formulations F271 to F299, various 
ratios of castor oil, PEG-200, and ethanol were used. The ternary phase 
diagram for formulations F301-F329, various ratios of castor oil, tween-80, 
and Transcutol P® were used, and for formulations F331 to F359, various 
ratios of castor oil, tween-80, and ethanol were used. It was observed 
that only 27 formulations F71, F81, F91, F101, F181, F191, F192, F201, F202, F211, F221, 
F222, F241, F242, F271, F272, F301, F302, F303, F311, F312, F313, F321, F322, F323, F331, and 
F351 have shown very good emulsification region with transparency after 
dilution in water. It is important to note here that formulations wherein 
tween-80 were used as a surfactant and Transcutol P® as cosurfactant in 
varying ratios of 1:1 (F301-303), 2:1 (F311-313), and 1:2 (F321-323), 
have shown the largest nanoemulsion area. Consequently, for further 
studies, these formulations have been selected.












PDI Drug loading of 
CRM (%)
Drug loading of 
DXH (%)
1 200 400 450 161.2 0.113 74.6 99.1
2 100 400 300 235.9 0.403 89.4 100
3 100 400 600 225 0.722 92.6 100
4 100 600 450 221 0.725 92.5 91.3
5 300 200 450 382.9 0.577 59.8 54
6 200 200 600 140.2 0.347 48.4 68.9
7 200 200 300 251.9 0.468 74.9 51.6
8 200 600 300 120.8 0.269 100 100
9 300 600 450 122.6 0.26 99.1 80.7
10 300 400 300 203.8 0.285 89.5 99.8
11 200 600 600 98.03 0.422 84.3 100
12 300 400 600 159.5 0.172 91.3 68.2
13 100 200 450 260.2 0.404 73.8 100
BBD: Box-Behnken design, SNEDDSs: Self-nanoemulsifying drug delivery systems, DHX: Duloxetine hydrochloride, CRM: Curcumin, PDI: Polydispersity index
Table 4: Solubility studies of CRM and DXH in different oils, 
surfactant, and cosurfactant
Components CRM DXH
Olive oil 3.95±0.03 6.13±0.08
Eucalyptus oil 5.15±0.015 48.11±0.17
Cottonseed oil 3.2±0.015 6.82±0.15
Sunflower oil 5.87±0.005 11.33±0.08
Castor oil 3.54±0.02 7.27±0.05
Peanut oil 4.51±0.02 2.04±0.04







Transcutol P 8.43±0.02 60.89±1.54
Ethanol 118.9±1.24 73.47±0.72
DHX: Duloxetine hydrochloride, CRM: Curcumin
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Experimental design using Box‑Behnken
The formula composition of CRM-DXH-SNEDDS as per DoE is shown in 
Table 3. A total of 13 experiments were designed by the software with 
two center points. Experiments were run in random order to increase 
the predictability of model.
The responses obtained for this study were well modeled by a linear 
function of independent variables; hence, first order polynomial was 
used for approximating the function as shown in equation 1 (Eq. 1).
y = β+β1x1+β2X2+β3X3+β4X4+€ (2)
Where, € represents noise or error, X represents independent variable, 
Y represents response, and β represents coefficient [31].
The values of responses y1 (mean droplet size), y2 (PDI), y3 (% drug 
loading of CRM), and y4 (% drug loading of DXH) ranged from 98.03 to 
178 nm, 0.113 to 0.725, 48.40 to 100%, and 51.6 to 100%, respectively. 
The ratio of maximum to minimum for the responses y1, y2, y3, and y4 is 
3.90, 6.41, 2.07, and 1.94, respectively; therefore, power transformation 
was not applied to the obtained values. ANOVA was applied to determine 
the significance and the magnitude of the effects of the main variables and 
their interactions. The regression model obtained was used to generate 
the counterplots for independent factors. The ANOVA table confirmed the 
adequacy of the model (i.e. F < 0.05) as shown in Table 5. It also identified 
the significant factors that affect the responses y1–y3 of SNEDDS.
“A perturbation graph was plotted to find those factors that have affected 
the response the most. A steep slope or curvature in a factor showed that 
the response was sensitive to that factor. A relatively flat line showed 
insensitivity to change in that particular factor” [29]. For mean droplet 
size (Fig. 2a) and PDI (Fig. 2b) all the three factors, i.e. ratio of oil (A), 
surfactant (B), and cosurfactant (C) were identified as significant model 
terms (Fig. 2a and b). However, factor A has shown the most significant 
effect on mean droplet size. For percentage drug loading of CRM, ratio 
of surfactant (B) was found to decipher the most significant effect (Fig. 
2c). Factors A and C have also shown their effect on percentage drug 
loading of CRM but these not so significant as that of factor B. In case of 
percentage drug loading of DXH, factors A (ratio of oil) and B (ratio of 
surfactant) were found to have a significant effect (Fig. 2d).
The final mathematical model in terms of coded factors as determined 
by design expert software is shown below in equations (2–4) for 
response y1–y4, respectively.
Table 5: Summary of ANOVA of Box‑Behnken screening design 
for CRM-DXH- SNEDDS
Response variables Regression parameters
R2 F cal P value
Mean droplet size (Y1) 0.938 11.94 0.0018
PDI (Y2) 0.966 21.74 0.0003
% Drug loading of CRM (Y3) 0.907 7.47 0.0073
% Drug loading of DXH (Y4) 0.500 3.70 0.0401
SNEDDSs: Self-nanoemulsifying drug delivery systems, DHX: Duloxetine 
hydrochloride, CRM: Curcumin, ANOVA: Analysis of variance, 
PDI: Polydispersity index
Fig. 1: Overlay plot showing the optimized batch of self-
nanoemulsifying drug delivery systems
Fig. 2: Perturbation plot showing the influence of individual factors on mean droplet size (y1) (a), polydispersity index (y2) (b), and 
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Mean droplet size (y1) = +161.20–9.16 × A–59.10 × B–23.71 × C–55.28 
× AB–8.35 × AC+22.23 × BC+69.40 × A2+16.08 × B2–24.55 × C2 (3)
PDI (y2) = +0.11–0.12 × A–0.015 × B+0.030 × C–0.16 × AB–0.11 × 
AC+0.068 × BC+0.20 A2+0.18 × B2+0.084 × C2 (4)
% Drug loading of CRM (y3) = +74.60–1.08 × A+14.87 × B–4.65 × 
C+5.15 × AB–0.35 AC+2.70 × BC+10.25 × A2–3.55 × B2+5.85 × C2 (5)
% Drug loading of DXH (y4) = +88.82–11.08 × A+12.19 × B–1.79 × C 
 (6)
Positive sign represented a synergistic effect, while a negative sign 
indicated an antagonistic effect. In case of y1, negative coefficients of A, 
B, and C of the model referred to decreased mean droplet size at a higher 
level of oil, surfactant, and cosurfactant, respectively. A decrease in mean 
droplet size of the formulation was observed with an increase in surfactant 
due to reduced interfacial tension and solubilization of oil. Furthermore, 
mixtures of surfactant and cosurfactant formed complete film around 
dispersed droplets and maintain droplet stability by strengthening their 
interfacial film. In addition, the surfactants are used to partition at a higher 
level into oil-water interface [29]. Response y2 referred to decrease in the 
PDI of the SNEDDS which represents the negative coefficients of A and 
B. Whereas positive coefficient of C indicated an increase in PDI with 
the increase in ratio of cosurfactant. In case of percentage drug loading 
of CRM (y3) and DXH (y4), negative coefficient of A and C indicated that 
with increase in the ratio of oil and cosurfactant, decrease in percentage 
drug loading of both the drugs was observed, whereas it increased with 
increase in the amount of surfactant (B).
Fig. 3: Contour plot showing the effect of Factor A and B on response Y1 at fixed levels of Factor C (2a); Factors A and C on response Y1 at 
fixed levels of Factor B (2b); Factors B and C on response Y1 at fixed levels of Factor A (2c); Factors A and B on response Y2 at fixed levels 
of Factor C (2d.); Factors A and C on response Y2 at fixed levels of Factor B (2e); Factors B and C on response Y2 at fixed levels of Factor A 
(2f); Factors A and B on response Y3 at fixed levels of Factor C (2g.); Factors A and C on response Y3 at fixed levels of Factor B (2h.); Factors 
B and C on response Y3 at fixed levels of Factor A (2i.); Factors A and B on response Y4 at fixed levels of Factor C (2j.); Factors A and C on 
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Based on ANOVA and perturbation plot factors A, B, and C were most 
ideal for generating 2D contour plots for response y1 to y4. Factor A 
was focused for generating 2D contour plot for response y2. Whereas, 
for Factor y4, Factors A and B were considered for generation of 2D 
contour plots.
Fig. 3a shows the effect of Factor A and B on response y1 at fixed levels 
of factor C. Fig. 3b shows the effect of Factors A and C on response y1 
at fixed levels of factor B. Fig. 3c shows the effect of Factors B and C on 
response y1 at fixed levels of Factor A. Fig. 3a-c shows that at a higher 
level of Factor A, B, and C, the mean droplet size was decreasing. This 
revealed that all the three factors have significantly contributed to 
decreasing the droplet size for the formulation of SNEDDS. From Fig. 3b 
and c, it is very pertinent that with the increase of the ratio of surfactant 
(B) and cosurfactant (C) in the formulation the maximum decrease in 
mean droplet size was observed. This could be attributed to the fact 
that the decrease in surface tension could be the main factor that would 
have caused the decrease in droplet size.
Fig. 3d shows the effect of Factor A and B on response y2 at fixed levels 
of Factor C. Fig. 3e shows the effect of Factors A and C on response y2 
on fixed levels of Factor B. Fig. 3f shows the effect of Factors B and C 
on response y2 at fixed levels of Factor A. Fig. 3d shows that with the 
increase in Factors A and B a decrease in PDI was observed. Whereas, 
Fig. 3e revealed that PDI decreased with an increase in A and increased 
with an increase in C. Similar types of results were observed in case of 
Fig. 3f, wherein, PDI decreased with an increase in A and increased with 
an increase in C.
Fig. 3g shows the effect of Factor A and B on response y3 at fixed levels 
of Factor C. Fig. 3h shows the effect of Factors A and C on response 
y3 on fixed levels of Factor B. Fig. 3i shows the effect of Factors B and 
C on response y3 at fixed levels of Factor A. Fig. 3g shows that with 
the increase in Factor A, decrease in percentage drug loading of CRM 
was observed, whereas, with increase in Factor B, the percentage drug 
loading of CRM increased.
In Fig. 3h, a decrease in percentage drug loading of CRM was observed 
with an increase in Factors A and C. Similar types of results were 
observed in case of Fig. 3i, wherein, percentage drug loading of CRM 
decreased with an increase in C and increased with an increase in B. 
In Fig. 3j, the effect of Factor A and B on response y4 at fixed levels of 
Factor C. In Fig. 3k, the effect of Factors A and C on response y4 on fixed 
levels of Factor B. From Fig. 3j, it was observed that percentage drug 
loading of DXH decreased with increase in Factor A and increased with 
the increase in Factor B, whereas percentage drug loading of CRM was 
decreased with increase in Factor C (Fig. 3k).
Optimization of formulation and processing parameters for CRM-
DXH SNEDDS using graphical optimization method
Optimization of CRM-DXH-SNEDDS was performed to find the levels of 
Factors A-C which gave mean droplet size y1 of 18.39–151 nm range, 
y2 in 0.077–0.375 range, y3 in 81.97–114.82% range, and y4 in 68.45–
126.07% range. Under this model predicted y1–y4 in required range 
at A, B, and C values of 217.23 μL (volume of oil), 521.6 μL (volume of 
surfactant), and 261.17 μL (volume of cosurfactant), respectively, for 
1000 μL (1 mL) of CRM-DXH-SNEDDS. Using these values of factors, 
three different batches of SNEDDS were prepared. Fig. 1 represents 
overlay plot showing the optimized batch of SNEDDS. The optimal 
ratio for the formulation for oil, surfactant, and cosurfactant was 
2.17:5.22:2.61, respectively. The zeta potential of optimized batch was 
−13.2 mV and droplet size of 113.14±1.14 nm. The drug loading (%) 
was 87.22±1.87% for CRM and 92.32±0.19 for DXH in the optimized 
formulation.
CONCLUSION
Present study deciphers successful optimization for the formulation of 
SNEDDS for oral delivery of two poorly soluble and gastric labile drugs, 
CRM and DXH, present in the form of a binary mixture. Castor oil, tween 
80, and Transcutol P® as the components and BBD were as a statistical 
tool used to optimize the formulation variables.
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